ESMO 2023 – Padcev hits its home run
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
ESMO 2023 – Amgen’s Steap1 project spurs cautious optimism
But toxicity will be closely watched in future trials.
ESMO 2023 – Lumakras still looks like a colorectal also-ran
And first data with a low dose are particularly unimpressive.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
